Consortium AI

Curated by Signal

Developer of small molecules for the treatment of rare diseases using AI platform

Overview

Consortium.AI is developing small molecules for the treatment of rare diseases. It is a venture between two companies, Insilico Medicines, and A2A Pharma. It is using an artificial intelligence platform to discover drugs. It is focused on Duchenne Muscular Dystrophy, Cancer and Crohn's Disease. The company has programs in drug discovery phase for oncology, Duchenne and Crohn disease.

Key facts

Founded: 2018
Headquarters: London, United Kingdom
Stage: Sign up to view
Industry: Life Sciences Technology

Contact

Primary office: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Laboklin
Provider of a complete range of diagnostic tests for veterinary surgeons
Life Sciences TechnologyManchester, United Kingdom
Orthoscape
Developer of patient-specific surgical treatments for orthopedic disorders
Life Sciences TechnologyBath, United Kingdom
NESO Technology
Developer of screening devices for the treatment of neural impairment
Life Sciences TechnologyLondon, United Kingdom

About Consortium AI

What does Consortium AI do?

Consortium.AI is developing small molecules for the treatment of rare diseases.

Where is Consortium AI headquartered?

Consortium AI is headquartered in London, United Kingdom.

When was Consortium AI founded?

Consortium AI was founded in 2018.

Which sector is Consortium AI in?

Consortium AI operates in Life Sciences Technology.

Who are Consortium AI's competitors?

Companies similar to Consortium AI include Laboklin, Orthoscape, and NESO Technology.